(2R)-1-[3-(3-cyanoazetidin-1-yl)sulfonylbenzoyl]-N-(2-phenylethyl)pyrrolidine-2-carboxamide
C24H26N4O4S — CID 175571166
Data last refreshed: (MolForge compound catalog, from PubChem)
About (2R)-1-[3-(3-cyanoazetidin-1-yl)sulfonylbenzoyl]-N-(2-phenylethyl)pyrrolidine-2-carboxamide
(2R)-1-[3-(3-cyanoazetidin-1-yl)sulfonylbenzoyl]-N-(2-phenylethyl)pyrrolidine-2-carboxamide (PubChem CID 175571166) has the molecular formula C24H26N4O4S and a molecular weight of 466.56 g/mol. Its IUPAC name is (2R)-1-[3-(3-cyanoazetidin-1-yl)sulfonylbenzoyl]-N-(2-phenylethyl)pyrrolidine-2-carboxamide.
Molecular Properties
| Compound Name | (2R)-1-[3-(3-cyanoazetidin-1-yl)sulfonylbenzoyl]-N-(2-phenylethyl)pyrrolidine-2-carboxamide |
|---|---|
| PubChem CID | 175571166 |
| Molecular Formula | C24H26N4O4S |
| Molecular Weight | 466.56 g/mol |
| Exact Mass | 466.17 |
| IUPAC Name | (2R)-1-[3-(3-cyanoazetidin-1-yl)sulfonylbenzoyl]-N-(2-phenylethyl)pyrrolidine-2-carboxamide |
| SMILES | N#CC1CN(S(=O)(=O)c2cccc(C(=O)N3CCC[C@@H]3C(=O)NCCc3ccccc3)c2)C1 |
| InChI | InChI=1S/C24H26N4O4S/c25-15-19-16-27(17-19)33(31,32)21-9-4-8-20(14-21)24(30)28-13-5-10-22(28)23(29)26-12-11-18-6-2-1-3-7-18/h1-4,6-9,14,19,22H,5,10-13,16-17H2,(H,26,29)/t22-/m1/s1 |
| InChIKey | IXKASWSGUFUQAZ-JOCHJYFZSA-N |
| XLogP | 1.79 |
| TPSA | 110.58 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 466.56 |
| LogP ≤ 5 | 1.79 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 175571166 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.